There is a marked increase in the global prevalence of obesity over the last decades with an estimated 1.9 billion adults living with overweight or obesity. This is associated with a sharp rise in prevalence of cardiorenal metabolic diseases such as type 2 diabetes mellitus, chronic kidney disease, and heart failure. With recent evidence of the efficacy of sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal protection and weight reduction, it is reasonable to investigate common causative pathways for cardiorenal metabolic diseases.

Saif Al-Chalabi

Akheel A Syed

Philip A Kalra

Smeeta Sinha

Cardiorenal Medicine

《心肾医学》杂志探讨了肥胖和其他代谢异常促进心脏和肾脏疾病（心肾代谢综合征）发病和进展的机制。它为推进研究和临床实践提供了一个跨学科平台，专注于转化问题。

The journal "CardioRenal Medicine" explores the mechanisms by which obesity and other metabolic disorders contribute to the onset and progression of cardiovascular and renal diseases (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for advancing research and clinical practice, focusing on translational issues.

《CardioRenal Medicine》杂志探讨肥胖及其他代谢异常如何促进心脏和肾脏疾病（心肾代谢综合征）的发生与发展。该期刊为研究和临床实践提供了一个跨学科的平台，专注于转化医学问题。

Category	Quartile
医学	4
医学, 心脏和心血管系统	4
医学, 泌尿学与肾脏学	4

Mechanistic Links between Central Obesity and Cardiorenal Metabolic Diseases

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
UROLOGY & NEPHROLOGY	2